作者: H.Paul Madore , M.K Estes , C.D Zarley , B Hu , S Parsons
DOI: 10.1016/S0264-410X(98)00319-3
关键词:
摘要: A parenterally administered rotavirus vaccine composed of virus-like particles (VLPs) is being evaluated for human use. VLPs bovine VP6 and simian VP7 (SA11, G3) proteins (6/7-VLPs) or VP2, VP6, (2/6/7-VLPs) were synthesized purified from Sf9 insect cells co-infected with recombinant baculoviruses. 6/7- 2/6/7-VLP (i.m.) in mice had comparable immunogenicity, but the 2/6/7-VLPs more homogeneous stable. The inclusion VP2 capsid contributed to particle formation stability. adjuvant QS-21 significantly enhanced immunogenicity over A10H saline alone. Equivalent serum neutralizing antibody responses induced range 1-15 microg/dose 5-20 QS-21. inactivated SA11 virus comparable. are a promising candidate delivered subunit vaccine.